{"id":507639,"date":"2021-06-29T08:53:05","date_gmt":"2021-06-29T12:53:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-provides-a-clinical-update-on-the-neutralizing-activity-of-its-covid-19-vaccine-on-emerging-variants-including-the-delta-variant-first-identified-in-india\/"},"modified":"2021-06-29T08:53:05","modified_gmt":"2021-06-29T12:53:05","slug":"moderna-provides-a-clinical-update-on-the-neutralizing-activity-of-its-covid-19-vaccine-on-emerging-variants-including-the-delta-variant-first-identified-in-india","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-provides-a-clinical-update-on-the-neutralizing-activity-of-its-covid-19-vaccine-on-emerging-variants-including-the-delta-variant-first-identified-in-india\/","title":{"rendered":"Moderna Provides a Clinical Update on the Neutralizing Activity of its COVID-19 Vaccine on Emerging Variants Including the Delta Variant First Identified in India"},"content":{"rendered":"

<\/p>\n

Moderna Provides a Clinical Update on the Neutralizing Activity of its COVID-19 Vaccine on Emerging Variants Including the Delta Variant First Identified in India<\/b><\/p>\n

Serum samples from eight participants obtained one week after second dose of the primary series in the Phase 1 clinical trial of the Moderna COVID-19 Vaccine <\/i><\/p>\n

Serum neutralization assays performed on emerging variants including 2 additional versions of the Beta variant (B.1.351) and 3 lineage variants of B.1.617, including the Kappa (B.1.617.1) and Delta (B.1.617.2) variants<\/i><\/p>\n

CAMBRIDGE, Mass.–(BUSINESS WIRE<\/a>)–Moderna, Inc.<\/a> (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced new results from in vitro neutralization studies of sera from individuals vaccinated with the Moderna COVID-19 Vaccine showing activity against variants of SARS-CoV-2. Vaccination with the Moderna COVID-19 Vaccine produced neutralizing titers against all variants tested, including additional versions of the Beta variant (B.1.351, first identified in South Africa), three lineage variants of B.1.617 (first identified in India), including the Kappa (B.1.617.1) and the Delta variants (B.1.617.2); the Eta variant (B.1.525, first identified in Nigeria); and the A.23.1 and A.VOI.V2 variants first identified in Uganda and Angola, respectively. These data were submitted as a preprint to bioRxiv<\/a><\/i>.\n<\/p>\n

\n\u201cAs we seek to defeat the pandemic, it is imperative that we are proactive as the virus evolves. We remain committed to studying emerging variants, generating data and sharing it as it becomes available. These new data are encouraging and reinforce our belief that the Moderna COVID-19 Vaccine should remain protective against newly detected variants,\u201d said St\u00e9phane Bancel, Chief Executive Officer of Moderna. \u201cThese findings highlight the importance of continuing to vaccinate populations with an effective primary series vaccine.\u201d\n<\/p>\n

\nThe study methodology was previously described in the letter to the editor<\/a> published in NEJM<\/i> on April 15, 2021 concerning the variants first identified in the U.K. (Alpha, B.1.1.7) and the Republic of South Africa (Beta, B.1.351) using serum samples from eight participants obtained one week after participants\u2019 second dose of the primary series in the Phase 1 clinical trial of the Moderna COVID-19 Vaccine. These most recent data include neutralization assays against additional variant strains. This additional analysis showed minimal impact on neutralizing titers against the Alpha and A.23.1 variants relative to those against the ancestral strain (D614G). This analysis also showed a modest reduction in neutralizing titers against the Delta (2.1-fold), Gamma (P.1, 3.2-fold), Kappa (3.3-3.4-fold), and Eta (4.2-fold) variants relative to those against the ancestral strain. Consistent with previous results, a 7.3 or 8.4-fold reduction in neutralizing titers was observed with the additional versions of the Beta variant relative to the ancestral strain. Additionally, an 8.0-fold reduction in neutralizing titers relative to the ancestral strain was observed with A.VOI.V2, the variant first identified in Angola, but currently not designated as a Variant of Concern or Interest.\n<\/p>\n

\nModerna is pursuing a clinical development strategy<\/a> against emerging variants to proactively address the pandemic as the virus continues to evolve. The Company is also studying mRNA-1273.211, a multivalent booster candidate which combines a 50-50 mix of mRNA-1273, Moderna\u2019s authorized vaccine against ancestral strains, and mRNA-1273.351 in a single vaccine at several dose levels in an ongoing study.\n<\/p>\n

About the Moderna COVID-19 Vaccine<\/b><\/p>\n

\nThe Moderna COVID-19 Vaccine is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein. On December 18, 2020, the U.S. FDA authorized the emergency use of the Moderna COVID-19 Vaccine in individuals 18 years of age or older. Moderna has received emergency (or other conditional, interim or provisional) authorization for use of its COVID-19 vaccine in adults from health agencies in more than 50 countries and an Emergency Use Listing (EUL) from the World Health Organization (WHO). Moderna has filed for emergency (or other conditional, interim or provisional) authorization for use of its COVID-19 vaccine in adolescents with health agencies in the European Union, Canada, the U.S., Switzerland and Japan.\n<\/p>\n

\nThe Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS) is supporting the continued research and development of the Company\u2019s COVID-19 vaccine development efforts with federal funding under contract no. 75A50120C00034. BARDA is reimbursing Moderna for 100 percent of the allowable costs incurred by the Company for conducting the program described in the BARDA contract. The U.S. government has agreed to purchase supply of mRNA-1273 under U.S. Department of Defense contract no. W911QY-20-C-0100.\n<\/p>\n

About Moderna<\/b><\/p>\n

\nIn 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna\u2019s capabilities have come together to allow the authorized use of one of the earliest and most effective vaccines against the COVID-19 pandemic.\n<\/p>\n

\nModerna\u2019s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and autoimmune diseases. Today, 24 development programs are underway across these therapeutic areas, with 14 programs having entered the clinic. Moderna has been named a top biopharmaceutical employer by Science<\/i> for the past six years. To learn more, visit www.modernatx.com<\/a>.\n<\/p>\n

AUTHORIZED USE<\/b><\/p>\n

\nModerna COVID-19 Vaccine is authorized for use under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older.\n<\/p>\n

IMPORTANT SAFETY INFORMATION<\/b><\/p>\n